Medical imaging AI companies collaborate to offer CINA-iPE on TeraRecon’s Eureka Clinical AI platform.
Cambridge, Mass., March 13, 2023 – ConcertAI’s TeraRecon, the advanced visualization and AI Clinical SaaS category leader, today announced a partnership to offer medical imaging AI specialist Avicenna.AI‘s CINA-iPE solution detecting the presence of incidental pulmonary embolisms as part of TeraRecon’s Eureka Clinical AI solution. Eureka Clinical AI and Intuition are KLAS top-rated solutions for clinical AI and advanced visualization.
Incidental pulmonary embolism is a frequent finding on routine CT scans of the chest, but only 25% of incidental emboli are reported at the initial interpretation. CINA-iPE is a CE-marked AI tool that analyzes images from CT scans and detects the presence of incidental pulmonary embolism immediately and with great immdiat consistency and accuracy. Delayed and missed findings are some of the most serious problems in diagnostic imaging, and incidental pulmonary embolism is a significant cause of mortality in the cancer patient population.
“We are committed to expanding the Eureka Clinical AI ecosystem with meaningful AI solutions to support our clinicians and care providers. Avicenna’s incidental pulmonary embolism detection algorithm is just one example of this commitment. This unique solution expands access to this critical diagnostic capability via our scalable Eureka Clinical AI platform,” said Dan McSweeney, President of TeraRecon.
Avicenna.AI provides healthcare AI solutions that use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. Using a combination of deep learning and machine learning technologies, the company’s solutions automatically detect and prioritize emergency cases within seconds, assess them for severity, and then seamlessly alert radiologists.
“We are delighted to empower the wide community of TeraRecon users with our innovative incidental pulmonary embolism AI algorithm. This global partnership brings healthcare providers closer to a more systematic reporting and treatment of life-threatening pulmonary emboli,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI.
Eureka Clinical AI is the leading AI SaaS imaging interpretation and clinical decision augmentation solution from ConcertAI’s TeraRecon. As the industry’s most broadly deployed platform, it is unique in that it is open to third-party AI algorithms, allowing consolidated management of all AI interpretation solutions with seamless PACS integrations. Multi-specialty care teams can see results and receive mobile alerts to confirm AI findings, ensuring optimal and timely patient interventions, management and coordinated care delivery.
Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more: https://www.terarecon.com/artificial-intelligence
About ConcertAI: ConcertAI is the leader in AI Saas Technologies for clinical research and clinical care and Real-World Evidence (RWE) solutions. Our mission is to accelerate insights and biomedical innovations, thereby improving outcomes for patients. For more information, visit us at www.concertai.com
About TeraRecon: Serving ~1,900 clinical sites globally, TeraRecon, a ConcertAI company, is a Best in KLAS solution provider for AI-empowered radiology, oncology, cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader for Advanced Visualization, TeraRecon solutions are independent of any one manufacturer’s imaging equipment or PACS system, allowing a single, unified, and simplified clinical workflow that can improve efficiencies and deliver actionable physician-guided insights. For more information, visit us at www.terarecon.com
About Avicenna.AI
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and to enhance clinicians’ workflow. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. www.avicenna.ai
